ClinicalTrials.gg
RecruitingNCT07097155ACCAUpdated May 12, 2026

Avocado Consumption and Cellular Aging in Breast Cancer Survivors

An interventional study of Daily Avocado Consumption in Telomere Length and Breast Cancer Females, sponsored by Institut Investigacio Sanitaria Pere Virgili. Recruiting at 1 site in Spain. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
449th of 805
120 · median 151
Started
2026
with 26 others
No phase
146 of 905
51 open now
Primary completion
2027-03
later than 140 of 284 live
Registered
855th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 449th largest by planned enrollment of the 805 interventional ones that give a count, is one of 27 that started in 2026, is one of 146 with no phase, reaches primary completion later than 140 of the 284 other live ones, and was the 855th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet. In recent years, avocado has drawn attention in nutritional research due to its unique nutritional profile.

Main objective: To evaluate the effect of consuming one avocado per day on biological aging-measured by telomere length-in breast cancer survivors, compared to a habitual diet (less than two avocados per week). Secondary objectives include changes in telomerase activity and biomarkers of inflammation and oxidative stress. Additional objectives include classical cardiovascular disease markers (glucose metabolism, lipid profile, blood pressure); anthropometric measurements; symptoms of depression and anxiety; quality of life and fatigue; and diet quality.

Methodology: A randomized controlled parallel-group trial involving 120 breast cancer survivors. Participants will be randomly assigned to either the intervention group (one avocado per day) or the control group (habitual diet with fewer than two avocados per week) and followed for 4 months. At baseline and the end of the intervention, a general questionnaire will be administered; blood and urine samples will be collected; anthropometric and blood pressure measurements will be taken; and diet, physical activity, symptoms of depression and anxiety, quality of life, and fatigue will be assessed. Mean changes from baseline to the end of the intervention in the primary outcome (telomere length) and secondary outcomes (inflammation, oxidative stress, classical cardiovascular disease markers, anthropometric measures, symptoms of depression and anxiety, quality of life, and diet) will be compared between the intervention and control groups using linear regression models.

03

Conditions studied

  • Telomere Length
  • Breast Cancer Females

Browse trials for

Keywords

  • Avocado consumption
  • Telomere length
  • Breast Cancer
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women diagnosed with primary breast cancer in stages I, II or III;
  • 40-65 years old at screening;
  • Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 10 years at the time of recruitment;
  • Currently consuming less than 2 avocados per week;
  • Signed the letter.

Exclusion criteria

Exclusion Criteria:

  • ;
  • Ductal carcinoma or lobular carcinoma in situ;
  • Breast cancer recurrence;
  • Cancer diagnosis other than breast cancer or non-melanoma skin cancer;
  • ≥40kg/m2;
  • Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months;
  • Allergy to latex;
  • Unwilling to consume avocado;
  • Immunodeficiency or -positive status;
  • Alcohol abuse (>50g/day);
  • Unstable use of plant sterols, mineral supplements, use of fibre supplements, fish oil, or antioxidants in the 4 weeks prior to enrolment, or plans to change this during the study;
  • Currently participating in any other randomized controlled trial;
  • Difficulty or impossibility of an adequate follow-up;
  • Inability or unwillingness to give written or to communicate with study personnel, or illiteracy;
  • Patients with an acute infection or inflammation (e.g., pneumonia) will be allowed to participate in the study 3 months after recovery.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Daily Avocado Consumption

    Participants assigned to the intervention group will be advised to follow their usual diet and to consume one avocado per day for the next four months. To ensure and facilitate compliance with the intervention, we will provide a leaflet with some recipes for incorporating avocados into their regular diet. Avocados will be provided for free. Participants will pick up avocados every two weeks from the study site.

    Other: Daily Avocado Consumption

  • No intervention
    Control - Usual Diet

    Participants allocated to the control group will be advised to follow their usual diet. Avocado consumption will not be encouraged.

Interventions

  • OtherDaily Avocado Consumption

    Participants follow their usual diet and consume one avocado per day for 4 months

06

What researchers measure

Primary outcomes

  1. Change from baseline in leukocyte telomere length

    Telomere length (TL) analysis will be performed employing the traditional real-time PCR(1) method (Cawthon 2009) by the QuantiTect Syber Green PCR kit (Qiagen). This approach employs the 36B4R single-copy gene as a reference for each sample. The measurements will be performed on a monochrome multiplex real-time quantitative PCR in a BioradCFX96 thermocycler on samples collected before and after the intervention. The data obtained by PCR will be expressed as the ratio of telomere/reference gene (T / S) as the ratio between the number of copies of the telomeric repeat (T) and a single copy gene (36B4F) (S)

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

Secondary outcomes

  1. Change from baseline in telomerase activity

    Telomerase activity will be assessed in white blood cells (PBMCs) using the TeloTAGGG Telomerase PCR ELISAPLUS method, a photometric enzyme immunoassay for quantitative determination of telomerase activity, utilizing the Telomeric Repeat Amplification Protocol (TRAP) (Sigma Aldrich).

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  2. Change from baseline in inflammatory markers

    Blood samples will be collected in the morning after 8-12h fast. Inflammatory markers (C-reactive protein, IL-1β, IL-6, TNFα, IL-8, IL-10) will be measured by commercial ELISA.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  3. Change from baseline in oxidative markers

    Blood samples will be collected in the morning after an 8-12h fast. Oxidized LDL will be measured in plasma. Spot urine will be collected, and 8-iso-prostaglandin F2α (8-isoprostanes) will be measured.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

Other outcomes

  1. Change from baseline in fasting glucose

    Fasting glucose in mg/dL will be measured by standardized methods

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  2. Change from baseline in glycated hemoglobin

    glycated hemoglobin (HbA1c) in % will be measured by standardized methods

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months

  3. Change from baseline in insulin resistance (HOMA-IR)

    Insulin resistance will be determined by HOMA-IR using plasma glucose and insulin.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months

  4. Changes from baseline in lipid profile

    HDL-cholesterol in mg/dL, LDL-cholesterol in mg/dL, triglycerides in mg/dL, and total cholesterol in mg/dL will be measured

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  5. Change from baseline in blood pressure

    Systolic and diastolic blood pressure will be measured using an automated device, after 5minutes of resting, in triplicate with a 1-minute interval between each measurement. The first measurement will be discarded, and the average of the two other measurements will be used for analysis.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  6. Change from baseline in body weight

    Body weight in kg will be measured, with the participants wearing light clothing and no shoes, using a high-quality electronic scale

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  7. Change from baseline in waist circumference

    Waist circumference in cm will be measured at the mid-point between the lowest rib and the iliac crest using an anthropometric tape

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  8. Change from baseline in BMI

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  9. Change from baseline in body composition

    Body composition will be assessed through TANITA

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  10. Change from baseline in the Functional Assessment of Cancer Therapy - Breast questionnaire

    Quality of life will be assessed through the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire. It is a 37-item instrument designed to measure 5 domains (physical, social, emotional, functional well-being, and breast-cancer subscale) of health-related quality of life in patients with breast cancer. Subscale scores will be added to derive: 1. FACT-B Trial Outcome Index (TOI): ranging from 0 to 96. 2. FACT-G total score: ranging from 0 to 108 3. FACT-B total score: ranging from 0 to 148 The higher the score, the better the outcome.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  11. Change from baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire

    Fatigue will be assessed through the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) questionnaire, a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. Subscale scores will be added to derive total scores: 1. FACIT-F Trial Outcome Index (TOI): ranging from 0 to 108 2. FACT-G total score: ranging from 0 to 108 3. FACIT-F total score: ranging from 0 to 160 4. Fatigue subscale: ranging from 0 to 52 The higher the score, the better the outcome.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  12. Change from baseline in diet quality

    Diet will be assessed using a validated semiquantitative food frequency questionnaire

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  13. Change from baseline in severity of depressive symptoms

    Severity of depressive symptoms will be assessed using the self-administered Patient Health Questionnaire-9 (PHQ-9), a nine-item instrument in which each item is scored from 0 to 3, yielding a total score ranging from 0 to 27. Higher PHQ-9 scores indicate greater severity of depressive symptoms.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

  14. Change from baseline in the severity of anxiety symptoms

    Severity of anxiety symptoms will be assessed using the self-administered Generalized Anxiety Disorder-7 (GAD-7) questionnaire, a seven-item instrument in which each item is scored from 0 to 3, yielding a total score ranging from 0 to 21. Higher GAD-7 scores indicate greater severity of anxiety symptoms.

    Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.

07

Study locations

1 of 1 sites recruiting
  • Unit for Public Health and Nutritional Epidemiology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili
    Reus, Tarragona 43201, Spain
    Recruiting
    • Nerea Becerra Tomás, PhD · Contactnerea.becerra@urv.cat · +34977759334
    • Nerea Becerra Tomás, PhD · Principal investigator
    • Victoria Arija, Professor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 14 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 31, 2025
StartActual
Jan 12, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Aug 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07097155
Lead sponsor
Institut Investigacio Sanitaria Pere Virgili
Responsible party
Nerea Becerra Tomás (Principal Investigator, Institut Investigacio Sanitaria Pere Virgili) — Principal investigator
First posted
Jul 31, 2025
Start date
Jan 12, 2026
Primary completion
Mar 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
May 12, 2026

Study contacts

Nerea Becerra Tomás, PhD
Contact
nerea.becerra@urv.cat
+34977759334
Victoria Arija, Professor
Contact
victoria.arija@urv.cat
+34977759334

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion